Aptevo Therapeutics Inc.
General ticker "APVO" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $5.7M (TTM average)
Aptevo Therapeutics Inc. does not follow the US Stock Market performance with the rate: -12.4%.
Estimated limits based on current volatility of 4.5%: low 1.31$, high 1.43$
Factors to consider:
- Total employees count: 37 as of 2024
- Top business risk factors: Delisting risk, History of losses, Going concern, Clinical trial delays, Intellectual property risks
- Current price 97.0% below estimated low
- Earnings for 9 months up through Q3 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [45.87$, 207.63$]
- 2025-12-31 to 2026-12-31 estimated range: [17.24$, 82.16$]
Financial Metrics affecting the APVO estimates:
- Negative: with PPE of -0.2 at the end of fiscal year the price was very high
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -1855.13 <= 0.33
- Negative: negative Net income
- Negative: negative Industry operating cash flow (median)
- Negative: -0.15 < Industry inventory ratio change (median), % of 0
- Negative: negative Industry operating income (median)
- Negative: Industry earnings per price (median), % of -16.34 <= 0
Short-term APVO quotes
Long-term APVO plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | $3.11MM | $0.00MM | $0.00MM |
| Operating Expenses | $31.75MM | $28.88MM | $24.60MM |
| Operating Income | $-28.64MM | $-28.88MM | $-24.60MM |
| Non-Operating Income | $35.66MM | $10.23MM | $0.47MM |
| R&D Expense | $17.88MM | $17.11MM | $14.38MM |
| Income(Loss) | $7.01MM | $-18.65MM | $-24.13MM |
| Other Income(Loss) | $1.01MM | $1.24MM | $0.00MM |
| Profit(Loss)* | $9.04MM | $-16.17MM | $-24.13MM |
| Stockholders Equity | $17.97MM | $12.22MM | $4.75MM |
| Assets | $34.22MM | $24.84MM | $15.59MM |
| Operating Cash Flow | $-21.02MM | $-11.73MM | $-23.79MM |
| Capital expenditure | $0.03MM | $0.00MM | $0.00MM |
| Investing Cash Flow | $-0.03MM | $0.00MM | $0.00MM |
| Financing Cash Flow | $-2.62MM | $6.00MM | $15.60MM |
| Earnings Per Share** | $57,710.69 | $-43,038.41 | $-1,747.79 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.